Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. Tuesday, 11th November, 2025 have 1. Approved the Unaudited Financial Results of the Company for ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Ishita Drugs & Industries approved the Unaudited Financial Results for the quarter and half year ended 30th September 2025. The statutory auditors issued a clean Limited Review Report with no qualifications or adverse remarks. The Board also reviewed its manufacturing facility upgradation project for compliance with Revised Schedule M; a civil contractor has been appointed, construction has commenced, and around Rs. 50 lakhs has already been spent on civil work. Progress was slower than planned due to heavier-than-usual rainfall and an extended monsoon this year. Key balance sheet items show inventory dropping sharply from Rs. 446.49 lakhs to Rs. 164.60 lakhs, current borrowings cut nearly in half from Rs. 381.35 lakhs to Rs. 193.23 lakhs, and total equity rising modestly to Rs. 1,123.53 lakhs. Cash flow from operations swung strongly positive at Rs. 412.24 lakhs for the half year versus a negative Rs. 363.71 lakhs in the full previous year.
For shareholders, the clean audit, debt reduction, and improved operating cash flow are positive signals on the financial health side, while the capex commitment to Schedule M compliance supports long-term manufacturing continuity but near-term margins could be modestly affected by the ~Rs. 50 lakhs civil spend and monsoon-related delays.